Caribou Biosciences spent the second quarter of 2026 setting the stage for the largest clinical event in its history. That event was alignment with the FDA on the design of ANTLER-3, its pivotal phase 3 trial of vispa-cel. The alignment was reached on May 7, 2026. June brought EHA presentations that placed the program in the same conversation as approved autologous CAR-T therapies. The strongest bull-case evidence is the 27-patient optimized vispa-cel subgroup. A single dose delivered a 82% overall response rate in that subgroup. The complete response rate reached 67%.
The strongest counterargument is that the company ended the quarter with $113.8M in cash and management guidance that those funds carry operations only to the end of 2027. That leaves a phase 3 trial requiring several hundred patients. The equity sits at a market capitalization near $168M on a share price close to $1.57. That price sits inside a fifty-two week band of $1.38 to $3.54. The enterprise value is around $83M. That enterprise value, barely above zero relative to six months of operating burn, says investors are paying mostly for the option value of the two clinical assets rather than for ongoing science spend.
The qualitative signal from this quarter is not the GAAP net loss improvement year over year. That move is largely mechanical because the prior-year quarter carried a $21.3M impairment cluster. The real signal is that R&D spending fell from $27.7M to $18.9M. That was an outcome of the April 2025 workforce reduction. Clinical activity continued at full pace. A company spending less while generating more clinical evidence is a structurally different company from the one that reported the prior-year period. The forward variable that determines the next year of trading is the source and structure of the ANTLER-3 financing. Management describes this in the August corporate update as a search across multiple non-dilutive and dilutive channels. A deeply discounted equity raise would compress per-share value even if the science remains intact. The bull case rests on an optimized readout that approaches autologous benchmark efficacy. That readout is paired with an RMAT-designated second asset. The second asset generated 92% overall response in that cohort. The complete response rate reached 83% across the 12-patient expansion.